Pfizer and BioNTech shared the first results of the study on the effect of the third dose. Accordingly, it was stated that the highest antibody levels were reached with the third dose taken between eight and nine months following the second dose.
Pfizer and BioNTech shared their first data on the impact of the third dose to U.S. regulators. Accordingly, the third dose in a period of eight to nine months after two doses of the vaccine ensured the highest antibody levels were achieved.
[penci_ads id=”penci_ads_1″]
The two companies will not use the emergency approval channel for the third dose, but will await the results of the final experiment involving a larger group.
- Advertisement -
